Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478
Acta Pharmaceutica Sinica B · 2026-09 · 16 (9) · 5884-5900
DOI: 10.1016/j.apsb.2026.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-09. Verfasst von Xiao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China National Outstanding Youth Science Fund Project, National Natural Science Foundation of China, Hainan Provincial Postdoctoral Science Foundation.
Abstract (Originalsprache)
Hotspot mutations in phosphoinositide 3-kinase alpha (PI3Kα), such as H1047R, E542K, and E545K, drive tumorigenesis across multiple cancer types. Orthosteric PI3Kα inhibitors are effective but have toxicity against wild-type PI3Kα, the emergence of resistance, and a narrow therapeutic index. Allosteric inhibitors such as RLY-2608 and STX-478 offer a promising path toward mutant-specific suppression, yet the structural basis for their selectivity and mechanisms of action remain elusive. Here, we report high-resolution cryogenic electron microscopy structures of RLY-2608- and STX-478-bound H1047R, E542K, and E545K, revealing a shared cryptic allosteric pocket, accessible only through a major conformational rearrangement of the activation loop that is stabilized in oncogenic mutants. While both inhibitors occupy this pocket, they have distinct interaction networks and propagate divergent allosteric activities: RLY-2608 induces large-scale remodeling of catalytic and membrane-interacting elements, whereas STX-478 reinforces autoinhibitory interfaces between p110α and p85α subunits. Comparative analysis provides structural insights into their differentiated potency and selectivity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
- Research Center for Deepsea Bioresources, Sanya 572025, China.
- Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medic…
- Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, School of Pharmacy, Hainan Medical University, Haikou 570228, China.
- Department of Chemistry, School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
Förderung
- National Natural Science Foundation of China National Outstanding Youth Science Fund Project
- National Natural Science Foundation of China
- Hainan Provincial Postdoctoral Science Foundation
Zitieren
APA
Liu, X., Chen, Y., Li, G., Chen, A., Zhou, Q., & Wang, M. W. (2026). Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478. Acta Pharmaceutica Sinica B, 16(9), 5884-5900. https://doi.org/10.1016/j.apsb.2026.07.003
Vancouver
Liu X, Chen Y, Li G, Chen A, Zhou Q, Wang MW. Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478. Acta Pharmaceutica Sinica B. 2026;16(9):5884-5900. doi:10.1016/j.apsb.2026.07.003
BibTeX
@article{Liu2026,
author = {Liu, Xiao and Chen, Yanyan and Li, Guanyi and Chen, Anqi and Zhou, Qingtong and Wang, Ming-Wei},
title = {Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {9},
pages = {5884--5900},
doi = {10.1016/j.apsb.2026.07.003}
}
EUVIMED